Zoetis Inc. (NYSE:ZTS) Stock Holdings Boosted by King Luther Capital Management Corp

King Luther Capital Management Corp raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,921,232 shares of the company's stock after acquiring an additional 7,846 shares during the quarter. Zoetis makes up 1.8% of King Luther Capital Management Corp's investment portfolio, making the stock its 9th largest position. King Luther Capital Management Corp owned 0.42% of Zoetis worth $379,194,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC boosted its stake in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company's stock valued at $25,000 after purchasing an additional 89 shares in the last quarter. Independence Bank of Kentucky boosted its stake in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company's stock worth $33,000 after acquiring an additional 130 shares in the last quarter. Private Wealth Management Group LLC bought a new stake in Zoetis during the fourth quarter worth about $33,000. Ramirez Asset Management Inc. bought a new stake in Zoetis during the third quarter worth about $35,000. Finally, Gladius Capital Management LP bought a new stake in Zoetis during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

ZTS stock traded down $1.60 during trading on Tuesday, hitting $172.79. 1,589,316 shares of the company's stock traded hands, compared to its average volume of 3,090,867. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The business has a fifty day simple moving average of $164.47 and a 200 day simple moving average of $179.61. The stock has a market capitalization of $78.84 billion, a price-to-earnings ratio of 33.68, a P/E/G ratio of 2.70 and a beta of 0.86.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter last year, the business earned $1.31 earnings per share. Zoetis's quarterly revenue was up 9.5% compared to the same quarter last year. As a group, research analysts expect that Zoetis Inc. will post 5.77 EPS for the current fiscal year.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares of the company's stock, valued at $2,725,267.59. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ZTS shares. Stifel Nicolaus decreased their target price on shares of Zoetis from $195.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, April 30th. HSBC decreased their price objective on shares of Zoetis from $230.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, May 8th. StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an "overweight" rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an "overweight" rating for the company in a report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.